The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Non-Alcoholic Steatohepatitis (NASH) Market?
The non-alcoholic steatohepatitis (NASH) market size has seen significant expansion in recent years. It is projected to increase from $6.06 billion in 2025 to $8.04 billion in 2026, indicating a compound annual growth rate (CAGR) of 32.7%. Historically, this growth can be ascribed to elements such as limited awareness regarding NASH, the absence of effective treatment solutions, a dependence on lifestyle modifications, the high prevalence of metabolic disorders, and a fragmented market landscape.
The non-alcoholic steatohepatitis (NASH) market is poised for significant growth in the coming years. It is projected to achieve a size of $24.32 billion in 2030, reflecting a compound annual growth rate (CAGR) of 31.9%. This anticipated growth during the forecast period is fueled by advancements in targeted therapies, increased healthcare expenditure, wider adoption of non-invasive diagnostics, an expanding range of pharmaceutical pipeline products, and rising collaborations in research and development. Key trends identified for this period include the increasing prevalence of obesity and type 2 diabetes, the development of non-invasive diagnostic instruments, escalating research into liver fibrosis treatments, an increase in personalized and targeted drug therapies, and the expansion of hospital and retail pharmacy infrastructures.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
What Major Growth Factors Are Impacting The Non-Alcoholic Steatohepatitis (NASH) Market?
The increasing incidence of obesity is fueling the demand within the non-alcoholic steatohepatitis (NASH) market moving ahead. Defined as an unhealthy accumulation of excessive fat or body weight exceeding healthy standards for a given height, obesity presents a significant health risk. With non-alcoholic fatty liver disease (NAFLD) becoming more common due to the growing obesity pandemic, NASH is anticipated to emerge as the primary cause of severe liver conditions in the coming decades, thus stimulating the need for NASH treatments and associated pharmaceuticals. As an illustration, data from May 2025, sourced from the Government Digital Service, a UK-based government body, indicated that in 2023 to 2024, the prevalence of overweight individuals (including obesity) among adults was greater in men at 69.7% compared to women at 59.2%. Conversely, the prevalence of obesity specifically was higher in women at 26.9% than in men at 26.2%. Consequently, the escalating number of obesity cases is projected to propel the expansion of the non-alcoholic steatohepatitis (NASH) market.
Which Segment Groups Define The Non-Alcoholic Steatohepatitis (NASH) Market Landscape?
The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –
1) By Dosage Form: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
What Trends Are Driving Changes In The Non-Alcoholic Steatohepatitis (NASH) Market?
Prominent companies within the non-alcoholic steatohepatitis (NASH) market are engaged in the creation of thyroid hormone receptor-beta (THR-beta) agonists aimed at boosting liver metabolism, diminishing liver fat accumulation, and improving liver function. Thyroid hormone receptor-beta (THR-beta) agonists are compounds designed to specifically activate the thyroid hormone receptor-beta subtype, a vital receptor influencing the regulation of metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a regulatory body based in the US, authorized Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist, as the inaugural treatment for adults with noncirrhotic NASH experiencing moderate to advanced liver scarring (fibrosis). Through the selective activation of the THR-beta receptor, Rezdiffra assists in regulating lipid metabolism, thereby resulting in a reduction of intrahepatic triglycerides and overall liver fat accumulation.
Who Are The Prominent Players Across The Non-Alcoholic Steatohepatitis (NASH) Market?
Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens
Access The Complete Non-Alcoholic Steatohepatitis (NASH) Market Report:
Which Region Leads The Non-Alcoholic Steatohepatitis (NASH) Market By Size?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Non-Alcoholic Steatohepatitis (NASH) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis (NASH) Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Biomarkers Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model